Curated News
By: NewsRamp Editorial Staff
September 10, 2026
GeoVax Appeals Nasdaq Delisting, Reaffirms Strategic Focus
TLDR
- GeoVax appeals Nasdaq delisting while advancing GEO-MVA and Gedeptin, aiming to regain compliance and secure strategic partnerships for long-term growth.
- GeoVax requested a Nasdaq hearing on October 13, 2026, to present a compliance plan, staying delisting and allowing continued trading under GOVX.
- GeoVax develops vaccines and immunotherapies for mpox, smallpox, and cancer, aiming to improve global health preparedness and patient outcomes.
- GeoVax's GEO-MVA vaccine for mpox and smallpox is advancing to a pivotal Phase 3 trial, while Gedeptin targets head and neck cancer.
Impact - Why it Matters
This news matters because GeoVax's ability to maintain its Nasdaq listing is critical for investor confidence and access to capital, which funds its vaccine and immuno-oncology programs. The outcome of the appeal could significantly affect the company's future and, by extension, the development of treatments for mpox, smallpox, and head and neck cancer. Additionally, the progress of GEO-MVA and Gedeptin® addresses global health preparedness and cancer treatment gaps, making this a story with far-reaching implications for public health and biodefense.
Summary
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, has provided an update on its Nasdaq listing status and reaffirmed its strategic priorities. The company is appealing a delisting determination from August 27, 2026, related to the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). A hearing before the Nasdaq Hearings Panel is scheduled for October 13, 2026, which has stayed any suspension or delisting action. As a result, GeoVax's common stock will continue to trade on The Nasdaq Capital Market under the symbol "GOVX" at least through the hearing and any extension period. CEO David Dodd expressed confidence in presenting a compliance plan, stating that the Nasdaq process does not alter the company's focus on execution.
GeoVax's priority program is GEO-MVA, an investigational Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox, advancing under an expedited regulatory pathway with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026. The company is also pursuing manufacturing innovations and strategic partnerships to support broader access and biodefense preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity, which has completed a Phase 1/2 trial in advanced head and neck cancer and is being advanced into combination strategies.
For more information, visit www.geovax.com. The original release is available on www.newmediawire.com.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, GeoVax Appeals Nasdaq Delisting, Reaffirms Strategic Focus
